Vcanbio Cell & Gene Engineering Corp Ltd
Vcanbio Cell & Gene Engineering Corp Ltd is a Chinese biotechnology company focused on cell and gene engineering, primarily generating revenue through the development and commercialization of biopharmaceutical products.
Business. Vcanbio Cell & Gene Engineering Corp Ltd (600645.SS) is a healthcare services and equipment company primarily engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the development and commercialization of cell and gene engineering solutions. Headquartered in China, the company is listed on the Shanghai Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Vcanbio Cell & Gene Engineering Corp Ltd (600645.SS) is a healthcare services and equipment company primarily engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the development and commercialization of cell and gene engineering solutions. Headquartered in China, the company is listed on the Shanghai Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.
Vcanbio Cell & Gene Engineering Corp Ltd maintains a strong liquidity position, with a current ratio of 1.82, indicating the company can cover its short-term liabilities with its short-term assets. The company's liquidity is rated as medium, and its debt-to-equity ratio is 0.02, suggesting a conservative capital structure with minimal reliance on debt financing.
In terms of profitability, the company's return on equity (ROE) is 3.07%, and its return on assets (ROA) is 2.15%. These figures are below the industry median for ROE and ROA in the Biotechnology sector, indicating that the company is underperforming relative to its peers in terms of generating returns for shareholders and asset utilization.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks if its primary market experiences a downturn.
Looking ahead, the company's growth trajectory appears modest. Based on the available financial data, there is no indication of significant revenue growth in the current or next fiscal year. The company's capital expenditures are negative, suggesting a reduction in investment in long-term assets, which may impact future growth potential.
The company's risk profile is characterized by a low dilution risk, with no significant dilution sources identified in the available data. However, the risk assessment notes that net cash is negative after subtracting total debt, which could signal potential liquidity constraints if cash flow from operations does not improve.
Recent events, including filings and transcripts, are not detailed in the available data. However, the company's ESG profile shows a high social pillar score of 8.97 and a moderate governance score of 38.89, with a perfect ESG controversies score of 100.00, indicating no major controversies.
- Vcanbio Cell & Gene Engineering Corp Ltd has a conservative capital structure with a low debt-to-equity ratio of 0.02.
- The company's ROE and ROA are below the industry median, indicating underperformance in profitability.
- The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company's growth trajectory is modest, with no significant revenue growth expected in the near term.
- The company has a low dilution risk, but its liquidity position is rated as medium, with a note on negative net cash after debt.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Vcanbio Cell & Gene Engineering Corp Ltd Market data — financials · 2026-05-27
- Vcanbio Cell & Gene Engineering Corp Ltd Market data — ESG · 2026-05-27